Fluoroquinolone Prophylaxis Is Highly Effective for the Prevention of Central Line-Associated Bloodstream Infections in Autologous Stem Cell Transplant Patients.

Authors

• Matthew Ziegler
• Daniel Landsburg
• David Pegues
• Warren Bilker
• Cheryl Gilmar
• Colleen Kucharczuk
• Theresa Gorman
• Kristen Bink
• Amy Moore
• Rebecca Fitzpatrick
• Edward A Stadtmauer
• Patricia Mangan
• Kelly Kraus
• Jennifer H Han

Publication/Presentation Date

5-1-2019

Abstract

Patients undergoing stem cell transplant (SCT) for the treatment of hematologic malignancy are at increased risk for central line-associated bloodstream infections (CLABSIs). The use of prophylactic antibiotics to prevent CLABSIs in the setting of autologous SCT is of unclear benefit. We aimed to evaluate the impact of levofloxacin prophylaxis on reducing CLABSIs in this high-risk population. Patients undergoing autologous SCT at a tertiary care hospital received levofloxacin prophylaxis from January 13, 2016 to January 12, 2017. Levofloxacin was administered from autologous SCT (day 0) until day 13, absolute neutrophil count > 500/mm

Volume

25

Issue

5

First Page

1004

Last Page

1010

ISSN

1523-6536

Published In/Presented At

Ziegler M, Landsburg D, Pegues D, Bilker W, Gilmar C, Kucharczuk C, Gorman T, Bink K, Moore A, Fitzpatrick R, Stadtmauer EA, Mangan P, Kraus K, Han JH. Fluoroquinolone Prophylaxis Is Highly Effective for the Prevention of Central Line-Associated Bloodstream Infections in Autologous Stem Cell Transplant Patients. Biol Blood Marrow Transplant. 2019 May;25(5):1004-1010. doi: 10.1016/j.bbmt.2018.11.023. Epub 2018 Nov 24. PMID: 30481595; PMCID: PMC6511289.

Disciplines

Medicine and Health Sciences

PubMedID

30481595

Department(s)

Hematology-Medical Oncology Division

Document Type

Article